| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 1g | |||
| Other Sizes |
| Targets |
Diclofensine targets the monoamine transporters for dopamine (DAT), norepinephrine (NET), and serotonin (SERT). It is a potent inhibitor of all three transporters, blocking the reuptake of these neurotransmitters from the synaptic cleft. The IC₅₀ values for blocking dopamine, norepinephrine, and serotonin in rat brain synaptosomes are 0.74 nM, 2.3 nM, and 3.7 nM, respectively. This triple reuptake inhibition is the basis for its antidepressant activity.
|
|---|---|
| ln Vitro |
In vitro, Diclofensine is a potent inhibitor of monoamine reuptake. It blocks the uptake of dopamine, norepinephrine, and serotonin by rat brain synaptosomes with high potency, as shown by its IC₅₀ values of 0.74 nM, 2.3 nM, and 3.7 nM, respectively. This activity profile makes it a classic example of a triple reuptake inhibitor (TRI).
|
| ln Vivo |
In vivo, Diclofensine acts as an antidepressant by increasing the synaptic concentrations of dopamine, norepinephrine, and serotonin. Its triple reuptake inhibition mechanism is expected to produce robust antidepressant effects. However, its clinical development was likely limited due to side effect profiles common to monoamine reuptake inhibitors. It is not currently used clinically.
|
| Enzyme Assay |
In vitro non-cell enzyme/receptor binding assays for Diclofensine typically involve measuring the inhibition of neurotransmitter uptake into synaptosomes (nerve terminals) prepared from rat brain. The synaptosomes are incubated with radiolabeled dopamine, norepinephrine, or serotonin in the presence of varying concentrations of Diclofensine. The amount of radioactivity taken up is measured, and IC₅₀ values are calculated from the inhibition curves.
|
| Cell Assay |
In vitro cell-based assays for Diclofensine use cell lines expressing the human monoamine transporters (hDAT, hNET, hSERT) to determine its potency against the human targets. Cells are incubated with the compound and a fluorescent or radiolabeled substrate, and the inhibition of substrate uptake is measured to calculate IC₅₀ values.
|
| Animal Protocol |
In vivo animal studies for Diclofensine have likely been conducted in rodent models of depression, such as the forced swim test or tail suspension test. The compound would be administered systemically, and its ability to reduce immobility time, indicating antidepressant-like activity, would be assessed. Brain levels of monoamines would also be measured to confirm target engagement.
|
| ADME/Pharmacokinetics |
Diclofensine has a molecular weight of 322.23 g/mol and a molecular formula of C₁₇H₁₇Cl₂NO. It has a LogP of 4.42, indicating moderate lipophilicity. As a small molecule, it is expected to be orally bioavailable and to cross the blood-brain barrier. The compound should be stored as a powder at -20°C for long-term stability.
|
| Toxicity/Toxicokinetics |
Diclofensine's toxicity profile is likely similar to other monoamine reuptake inhibitors, which can include cardiovascular effects, gastrointestinal disturbances, and central nervous system side effects. At high doses, it may cause serotonin syndrome or hypertensive crisis. Comprehensive toxicological data are not publicly available as the compound is a research tool.
|
| Additional Infomation |
Diclofensine (Ro-8-4650) is a potent triple reuptake inhibitor of dopamine, norepinephrine, and serotonin, investigated for its antidepressant properties. It is a classic research compound used to study the pharmacology of monoamine transporters and the development of antidepressants. Its high potency and balanced inhibition of all three transporters make it a valuable tool compound. Not approved for clinical use; intended for research purposes only.
|
| Molecular Formula |
C17H17NOCL2
|
|---|---|
| Molecular Weight |
322.22898
|
| Exact Mass |
321.068
|
| CAS # |
67165-56-4
|
| Related CAS # |
Diclofensine hydrochloride;34041-84-4
|
| PubChem CID |
68871
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
422.6±45.0 °C at 760 mmHg
|
| Flash Point |
209.4±28.7 °C
|
| Vapour Pressure |
0.0±1.0 mmHg at 25°C
|
| Index of Refraction |
1.591
|
| LogP |
4.42
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
21
|
| Complexity |
354
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CN1CC2=C(C=CC(OC)=C2)C(C3=CC=C(Cl)C(Cl)=C3)C1
|
| InChi Key |
ZJDCGVDEEHWEIG-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C17H17Cl2NO/c1-20-9-12-7-13(21-2)4-5-14(12)15(10-20)11-3-6-16(18)17(19)8-11/h3-8,15H,9-10H2,1-2H3
|
| Chemical Name |
4-(3,4-dichlorophenyl)-7-methoxy-2-methyl-3,4-dihydro-1H-isoquinoline
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.1034 mL | 15.5169 mL | 31.0337 mL | |
| 5 mM | 0.6207 mL | 3.1034 mL | 6.2067 mL | |
| 10 mM | 0.3103 mL | 1.5517 mL | 3.1034 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
